Viñuela 1994 | Brilstra 1999 | Byrne 1999 | ISAT 2002 | Henkes 2004 | Holmin 2008 | Resat 2010 | CLARITY 2010 | Murias 2013 | |
---|---|---|---|---|---|---|---|---|---|
WFNS at hospitalization | |||||||||
I | 20.3% | 51.1% | 63% | 26% | 13.7% | 20% | 44.2% | 38.6% | |
II | 26.1% | 24.6% | 25% | 25.3% | 53.7% | 30% | 21.5% | 13.1% | |
III | 30% | 13.6% | 6% | 21.1% | 15% | 20% | 3.7% | 6.7% | |
I—III | 76.4% | 80% | 89.3% | 94% | 72.4% | 82.4% | 70% | 69.4% | 58.4% |
IV | 17.1% | 6.9% | 4% | 15.9% | 14% | 20% | 16.3% | 23.9% | |
V | 6.5% | 3.8% | 2% | 8% | 3.6% | 10% | 14.3% | 17.5% | |
IV—V | 23.6% | 20% | 10.7% | 6% | 23.9% | 17.6% | 30% | 30.6% | 41.6% |
Total | 403 | 509 | 317 | 1073 | 1087 | 320 | 4786 | 773 | 251 |
mRS 1 year | |||||||||
0 | 19.1% | 53% | 53.1% | 38% | |||||
1 | 29.1% | 19.1% | 19.1% | 15% | |||||
2 | 25.7% | 13% | 45% | 10% | |||||
0–2 | 84.9% | 89.2% | 81.4% | 73.9% | 75% | 85.2% | 75% | 76.7% | 63% |
3 | 10.1% | 8.7% | 2.9% | 6% | |||||
4 | 3.2% | 3% | 2.4% | 11% | |||||
5 | 5.8% | 0.4% | 1.8% | 5% | |||||
6 | 7.5% | 7.0% | 6% | 2.7% | 16.3% | 15% | |||
3–6 | 15.1% | 10.8% | 18.6% | 26.1% | 25% | 14.8% | 25% | 23.3% | 37% |
It is worth noting that ISAT is a prospective trial that compares endovascular and surgical therapies, CLARITY is the only trial that analyses endovascular treatment as a first choice treatment for non-selected patients, and the Brilstra study is a meta-analysis. The results are shown in terms of the independence and mortality of our series compared with those in related articles, using the modified Rankin Scale (mRS) analysis after 1 month.
ISAT, International Subarachnoid Aneurysm Trial; WFNS, World Federation of Neurosurgical Societies.